3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
4
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pinealoma
1
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Interventions
pembrolizumab
1
durvalumab
1
atezolizumab
1
Standard of Care
1
Immunotherapy
1
Control Groups
1
Blood Specimen Collection
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Immunotherapy
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled